Between Months 3 and 6, abdominal fat begins to decrease
Zepbound vs Wegovy: Head-to-Head Clinical Trial Results One of the most significant developments in obesity medicine came with the SURMOUNT-5 trialthe first direct comparison of Zepbound vs Wegovy
Gallbladder In the SCALE-trial, high-dose liraglutide for the treatment of obesity was associated with an increased risk of gallbladder events compared to placebo (2.5% versus 1.0% of patients, respectively) (84)
This sparked one of the most strenuous weight loss research studies in modern times which showed at higher doses and given by injection once weekly patients saw up to a 15% reduction in total body weight
In large-scale studies: 2,6,7 Average weight loss ranges from 2-6% of body weight (approximately 5-12 pounds for most people) About one-third of patients lose at least 5% of their body weight within a year Weight loss is sustained long-termstudies show benefits lasting up to 15 years with continued use Results improve with adherencethe longer people take it consistently, the better the outcomes Importantly, these positive changes occur even in people without type 2 diabetes